Clinical Trials Directory

Trials / Completed

CompletedNCT02396238

Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)

Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
88 (actual)
Sponsor
Cytori Therapeutics · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand dysfunction due to scleroderma.

Detailed description

The STAR Trial is a prospective, randomized, multi-center device trial intended to assess safety and efficacy of subcutaneous administration of Celution processed ADRCs into fingers of patients with hand dysfunction due to scleroderma. Following informed consent and screening evaluations, eligible subjects will undergo pre-operative testing. Subjects will then undergo fat harvest through small volume liposuction under local anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs for immediate subcutaneous administration under local anesthesia. Subjects will be randomly assigned to receive ADRCs (40 million cells) or a visually-matched placebo in a 1:1 ratio. All subjects will receive subcutaneous administration of test substance (ADRC or placebo) into all fingers of both hands. Following completion of all 48 week visits and database lock, placebo treated subjects will be offered treatment with their ADRCs cells should they continue to qualify according to the inclusion/exclusion criteria and should they wish to be treated with ADRCs and agree to the fat harvest procedure.

Conditions

Interventions

TypeNameDescription
DEVICECelution DeviceADRCs prepared using the investigational Celution Device
OTHERPlaceboPlacebo

Timeline

Start date
2015-05-15
Primary completion
2017-09-19
Completion
2018-05-22
First posted
2015-03-24
Last updated
2018-06-04

Locations

19 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT02396238. Inclusion in this directory is not an endorsement.